Latest: FDA Approves New Biosimilar for Oncology Treatment

Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC

0 Mins
Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago